Side Effects: The Nose Knows - Summary - MDSpire

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

  • By

  • Kerri Miller

  • March 18, 2026

  • 6 min

Share

Objective:

To explore the detection of pre-clinical Alzheimer's disease through olfactory epithelium biopsies.

Key Findings:
  • Pre-clinical Alzheimer's group showed activated CD8 memory T cells in olfactory tissue at rates nearly triple that of controls (13.4% vs. 4.1%, p=0.017).
  • The olfactory T-cell activation pattern in pre-clinical Alzheimer's mirrors findings in the CSF of patients with clinical Alzheimer's.
  • A combined immune plus neuronal gene module classified preclinical versus control with an AUC of 0.81.
Interpretation:

Olfactory loss in older patients may indicate early biological changes associated with Alzheimer's disease, suggesting the nose could serve as a diagnostic tool.

Limitations:
  • The biopsy approach is not yet clinical.
  • The study sample size was small (n=22).
Conclusion:

The findings highlight the potential of olfactory biopsies as a diagnostic method for early Alzheimer's detection, reframing the importance of olfactory health.

Original Source(s)

Side Effects: The Nose Knows

  • by Kerri Miller

  • March 18, 2026

Related Content

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.